METIS TECHBIO-P Shares Surge Over 7% in Morning Session on Strategic Alliance News

Stock News06-15

Shares of METIS TECHBIO-P (07666) experienced a significant rise of over 7% during the morning trading session. At the time of writing, the stock was up 7.58%, trading at HK$14.25 with a turnover of HK$1.78 million.

The upward movement follows the company's recent announcement of a strategic alliance with Deerfield, a premier global health investment and innovation platform. Under this partnership, Deerfield will engage in extensive collaboration with METIS TECHBIO-P concerning its proprietary AI-powered nano-delivery platform, NanoForge, its associated solution portfolio, and key pipeline projects. The focus will be on global clinical development and commercial expansion initiatives.

The NanoForge platform is reported to have established a comprehensive framework that integrates AI-driven protein generation, in vivo delivery technologies, and the development of next-generation immunotherapies. A key component, the AiProtein platform, is designed for the rapid discovery and optimization of novel therapeutic proteins. This includes T-cell engagers (TCEs), in vivo protein therapies, and other advanced immunomodulatory treatment modalities.

The strategic alliance is intended to deeply integrate METIS TECHBIO-P's proprietary and differentiated technologies in AI-driven protein engineering, in vivo immunotherapy, and programmable biologics with Deerfield's extensive industry experience and specialized capabilities in translational medicine, clinical development, healthcare innovation, and global partnerships.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192338308?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192338308","market":"sh","top_or_hot":-1,"title":"METIS TECHBIO-P Shares Surge Over 7% in Morning Session on Strategic Alliance News","media":"Stock News","content":"<p>Shares of <b>METIS TECHBIO-P</b> (<b>07666</b>) experienced a significant rise of over 7% during the morning trading session. At the time of writing, the stock was up 7.58%, trading at HK$14.25 with a turnover of HK$1.78 million.<br><br>\nThe upward movement follows the company's recent announcement of a strategic alliance with Deerfield, a premier global health investment and innovation platform. Under this partnership, Deerfield will engage in extensive collaboration with METIS TECHBIO-P concerning its proprietary AI-powered nano-delivery platform, NanoForge, its associated solution portfolio, and key pipeline projects. The focus will be on global clinical development and commercial expansion initiatives.<br><br>\nThe NanoForge platform is reported to have established a comprehensive framework that integrates AI-driven protein generation, in vivo delivery technologies, and the development of next-generation immunotherapies. A key component, the AiProtein platform, is designed for the rapid discovery and optimization of novel therapeutic proteins. This includes T-cell engagers (TCEs), in vivo protein therapies, and other advanced immunomodulatory treatment modalities.<br><br>\nThe strategic alliance is intended to deeply integrate METIS TECHBIO-P's proprietary and differentiated technologies in AI-driven protein engineering, in vivo immunotherapy, and programmable biologics with Deerfield's extensive industry experience and specialized capabilities in translational medicine, clinical development, healthcare innovation, and global partnerships.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>METIS TECHBIO-P Shares Surge Over 7% in Morning Session on Strategic Alliance News</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMETIS TECHBIO-P Shares Surge Over 7% in Morning Session on Strategic Alliance News\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-15 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>METIS TECHBIO-P</b> (<b>07666</b>) experienced a significant rise of over 7% during the morning trading session. At the time of writing, the stock was up 7.58%, trading at HK$14.25 with a turnover of HK$1.78 million.<br><br>\nThe upward movement follows the company's recent announcement of a strategic alliance with Deerfield, a premier global health investment and innovation platform. Under this partnership, Deerfield will engage in extensive collaboration with METIS TECHBIO-P concerning its proprietary AI-powered nano-delivery platform, NanoForge, its associated solution portfolio, and key pipeline projects. The focus will be on global clinical development and commercial expansion initiatives.<br><br>\nThe NanoForge platform is reported to have established a comprehensive framework that integrates AI-driven protein generation, in vivo delivery technologies, and the development of next-generation immunotherapies. A key component, the AiProtein platform, is designed for the rapid discovery and optimization of novel therapeutic proteins. This includes T-cell engagers (TCEs), in vivo protein therapies, and other advanced immunomodulatory treatment modalities.<br><br>\nThe strategic alliance is intended to deeply integrate METIS TECHBIO-P's proprietary and differentiated technologies in AI-driven protein engineering, in vivo immunotherapy, and programmable biologics with Deerfield's extensive industry experience and specialized capabilities in translational medicine, clinical development, healthcare innovation, and global partnerships.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIPO","symbol_name":"Defiance AI and Power Infrastructure ETF","start_time":0,"source_url":"","article_id":"1192338308","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192338308","pubTimestamp":1781487989,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of METIS TECHBIO-P (07666) experienced a significant rise of over 7% during the morning trading session. At the time of writing, the stock was up 7.58%, trading at HK$14.25 with a turnover of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIPO":"Defiance AI and Power Infrastructure ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","07666":"剂泰科技-P","BK4588":"碎股","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","AGIX":"通用人工智能 ETF-AGIX","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF"},"translate_title":"METIS TECHBIO-P股价因战略联盟消息早盘飙升逾7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07666":1,"CHAT":1,"ARTY":1,"VXUS":1,"AIPO":1,"AGIX":1},"content_text":"Shares of METIS TECHBIO-P (07666) experienced a significant rise of over 7% during the morning trading session. At the time of writing, the stock was up 7.58%, trading at HK$14.25 with a turnover of HK$1.78 million.\nThe upward movement follows the company's recent announcement of a strategic alliance with Deerfield, a premier global health investment and innovation platform. Under this partnership, Deerfield will engage in extensive collaboration with METIS TECHBIO-P concerning its proprietary AI-powered nano-delivery platform, NanoForge, its associated solution portfolio, and key pipeline projects. The focus will be on global clinical development and commercial expansion initiatives.\nThe NanoForge platform is reported to have established a comprehensive framework that integrates AI-driven protein generation, in vivo delivery technologies, and the development of next-generation immunotherapies. A key component, the AiProtein platform, is designed for the rapid discovery and optimization of novel therapeutic proteins. This includes T-cell engagers (TCEs), in vivo protein therapies, and other advanced immunomodulatory treatment modalities.\nThe strategic alliance is intended to deeply integrate METIS TECHBIO-P's proprietary and differentiated technologies in AI-driven protein engineering, in vivo immunotherapy, and programmable biologics with Deerfield's extensive industry experience and specialized capabilities in translational medicine, clinical development, healthcare innovation, and global partnerships.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192338308","isCrawlerRequest":true}